Asia
This week had a few disappointing clinical trials, as do most weeks, but it also had a number of significant successes. Here’s a look at some of the clinical trials that met their primary endpoints this week.
Chinese companies and investors continue to flex their financial muscles with a series of deals this week that highlight the continued growing impact that country is having on the global pharmaceutical and biotech landscape.
Days after the U.S. Food and Drug Administration provided an expedited path forward for Sage Therapeutics’ depression treatment SAGE-217, the company snagged a deal worth $575 million.
Biogen signed an exclusive option deal with Tokyo-based TMS for TMS-007 and backup compounds.
Luye Pharma Group Ltd., announced today it is expanding its relationship with U.S. biotech firm Elpis Biopharmaceuticals Corp., to work on dual-target based therapies for cancer patients who fail to respond to current treatment.
Blueprint Medicines Corporation and privately held CStone Pharmaceuticals have entered into a partnership to develop and commercialize avapritinib, BLU-554 and BLU-667 in mainland China, Hong Kong, Macau and Taiwan, either as monotherapies or combination therapies.
There’s plenty of news coming out of the American Society of Clinical Oncology (ASCO) Annual Meeting behind held in Chicago. Here’s a look at a few more of the top stories.
There are plenty of great scientific research stories out this week from a tool to delete gene products to the growth of whole muscles incorporated into a biohybrid robot. Here’s a look at just a few of them.
Following the long holiday weekend, three pharma companies began the week with good news as the U.S. Food and Drug Administration awarded their therapies with Priority Review Status.
Brii Biosciences is launching to accelerate the development and delivery of breakthrough drugs in China with $260 million in financial backing.
PRESS RELEASES